Journal
IMMUNITY
Volume 55, Issue 1, Pages 3-+Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2021.12.010
Keywords
-
Categories
Funding
- U.S. National Institutes of Health [CA121113]
- Bloomberg-Kimmel Institute for Cancer Immunotherapy
Ask authors/readers for more resources
The study challenges previous associations between germline HLA genotypes and immunotherapy outcomes, indicating that germline HLA genotypes and diversity alone are not independent biomarkers of anti-PD1 clinical efficacy.
Human leukocyte antigen (HLA) molecules are critical mediators of anti-tumor immune responses. In this issue of Immunity, Chhibber et al. (2021) challenge previous associations between germline HLA zygosity and immunotherapy outcomes, demonstrating that germline HLA genotypes and diversity alone are not independent biomarkers of anti-PD1 clinical efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
